

[RISE]

Drew University Research
Institute for Scientists Emeriti

honors the

Seattle Genetics Drug Discovery Team

with the

HEROES IN DRUG DISCOVERY AWARD



Tues. October 27th, 7pm
Online presentation
Learn more & register

drew.edu/heroes

Join us for a free talk by Dr. Peter Senter
Antibody Drug Conjugates for Cancer Therapy:
From Early Stage Research to Clinically Approved Drugs



Dr. Peter Senter is currently Vice President of Chemistry and Distinguished Research Fellow at Seattle Genetics. During his career, Dr. Senter has published over 150 papers and has won several awards for the drug discovery teams' accomplishments. A few examples include Lectureships at several major universities, the Illinois Alumni Achievement Award, the American Chemical Society's Hero in Chemistry award and most importantly, the World Antibody-Drug Conjugate award for long standing contributions to this growing field.

Dr. Senter will describe the successful cancer research program at Seattle Genetics utilizing antibody-drug conjugates. Seattle Genetics has discovered and developed three marketed products, ADCETRIS for lymphoma, PADCEV for metastatic urothelial cancer, TUKYSA for metastatic HER2-positive breast cancer with additional compounds in the pipeline.

This event is supported by a grant from Pfizer and administered by the Independent College Fund of NJ

